title: Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma.
abstract: BACKGROUND
  Feline mammary carcinomas (FMC) are locally invasive and highly metastatic tumors. Because of the high metastatic potential, patients often are treated with adjuvant doxorubicin-based chemotherapy, but little data exist to evaluate the effect of this strategy.
  
  
  OBJECTIVE
  Adjuvant doxorubicin-based chemotherapy improves outcome for FMC compared with surgery alone.
  
  
  METHODS
  Cats with naturally occurring, biopsy-confirmed FMC treated with either surgery alone (Sx) or with surgery plus adjuvant doxorubicin-based chemotherapy (Sx + Chemo).
  
  
  METHODS
  Retrospective cohort study. Clinical data were collected and compared to identify differences between groups. Outcome results were determined and compared. Prognostic factors for disease-free survival (DFS) and overall survival were evaluated.
  
  
  RESULTS
  Seventy-three cats were evaluated, of which 37 were in the Sx group and 36 in the Sx + Chemo group. No differences in clinical data were found between Sx and Sx + Chemo groups. Median DFS times for the Sx and Sx + Chemo groups were 372 and 676 days, respectively (P= .15) and median survival times (ST) were 1,406 and 848 days, respectively (P= .78). For cats that underwent a unilateral radical mastectomy, ST was significantly longer for the Sx + Chemo compared with the Sx group (1,998 versus 414 days, respectively; P= .03).
  
  
  CONCLUSIONS
  This study did not find a benefit to adjuvant doxorubicin-based chemotherapy in cats with FMC. Additional studies are required to determine whether patient subgroups with negative prognostic factors may benefit from adjuvant chemotherapy.
authors.affiliation: Department of Clinical Studies, Matthew J. Ryan Veterinary Hospital, University of Pennsylvania, Philadelphia, PA, USA. cmcneill@vet.upenn.edu
authors.forename: C J
authors.initials: CJ
authors.lastname: McNeill
authors.forename: K U
authors.initials: KU
authors.lastname: Sorenmo
authors.forename: F S
authors.initials: FS
authors.lastname: Shofer
authors.forename: L
authors.initials: L
authors.lastname: Gibeon
authors.forename: A C
authors.initials: AC
authors.lastname: Durham
authors.forename: L G
authors.initials: LG
authors.lastname: Barber
authors.forename: J L
authors.initials: JL
authors.lastname: Baez
authors.forename: B
authors.initials: B
authors.lastname: Overley
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000601:surgery; D002415:Cats; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D008297:Male; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide